Tradestie Institutional Equity Comparison Engine

IIF vs RDY โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

RDY Overall Edge

RDY Captures Institutional Edge (3โ€“0 Pillars ยท 9โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Dr. Reddy's Laboratories Limited American Depositary Shares (RDY) driven by superior Valuation, Growth & Margin, Momentum & Technical. Fundamentally, IIF trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus RDY at 31.6x Forward P/E and 9.1% operating margin (-1.5% YoY). In options structure, IIF sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against RDY sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner RDY
IIF N/M vs RDY 31.6x Fwd P/E
Growth & Margin Winner RDY
Op Margin N/A vs 9.1% ยท YoY N/A vs -1.5%
Momentum & Technical Winner RDY
1Y -12.2% vs +6.0% ยท 52W Pos 47% vs 78%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
IIF NYSE
Morgan Stanley India Investment Fund, Inc.
Institutional Equity
$23.43
-0.38% 1D
Market Cap $253.3M
1M Return +7.33%
1Y Return -12.21%
Forward P/E N/M
Unified AI Score
31.5 / 100 SELL
Tech 5.0 Fund 31.0 Flow 50.0 Mom 54.0
RDY NYSE
Dr. Reddy's Laboratories Limited American Depositary Shares
Pharmaceutical Preparations
$14.70
-0.27% 1D
Market Cap $12.3B
1M Return +12.47%
1Y Return +5.98%
Forward P/E 31.6x
Unified AI Score
34.7 / 100 SELL
Tech 17.0 Fund 34.0 Flow 50.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: IIF -12.21% RDY +5.98% Spread: +18.19 pp (RDY Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
IIF TTM Op. Margin: N/A RDY TTM Op. Margin: 9.1%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IIF vs RDY. Trailing 12-month operating profitability (IIF N/A vs RDY 9.1%) and valuation multiples (IIF N/M vs RDY 31.6x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: IIF (1) vs RDY (9)
Institutional Metric IIF RDY Criterion Row Winner
Market Capitalization Scale $253.3M $12.3B Larger Scale RDY
Trailing P/E Ratio Valuation N/M 40.9x Lower Multiple RDY
Forward P/E Ratio Valuation N/M 31.6x Lower Multiple RDY
Revenue Growth (YoY) Growth N/A -1.5% Higher Growth RDY
Operating Margin (TTM) Profitability N/A 9.1% Higher Margin RDY
Net Profit Margin Profitability N/A 8.5% Higher Margin RDY
Return on Equity (ROE) Capital Efficiency N/A 7.3% Higher ROE RDY
52-Week Range Position Momentum 47% ($20โ€“$28) 78% ($11โ€“$16) Stronger Trend RDY
Beta / 30D Volatility Risk Regime 0.69ฮฒ ยท 21% Vol 0.39ฮฒ ยท 24% Vol Lower Realized Risk IIF
Unified Institutional Score Composite Signal 31.5 / 100 (SELL) 34.7 / 100 (SELL) Higher Composite RDY

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full IIF vs RDY Buy Guide
IIF UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live IIF Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
RDY UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live RDY Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither IIF nor RDY registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.